Drug Trial Radar · NCT07881120
Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Apr 2030
Study completion Apr 2031
Sponsor
- Lead sponsor
- Beeline Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or without systemic lupus, whose disease has not responded to or who cannot tolerate antimalarial therapy. Participants are assigned by chance to receive afimetoran or a matching placebo capsule once daily for 24 weeks, in addition to their existing standard lupus care. Neither participants nor study staff know which treatment is given. The study is run in two stages under a single protocol. Stage 1 compares two doses of afimetoran with placebo to select the dose. Stage 2 compares the selected afimetoran dose with placebo to confirm efficacy and safety. After the 24-week placebo-controlled period, all participants receive afimetoran for a further 28 weeks, for a total of 52 weeks of treatment. The main measures of benefit are the change in the CLASI-A skin activity score and the proportion of participants achieving a 70% improvement in that score at Week 24.
Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Systematic Lupus Erythematosus
Interventions
AfimetoranDrug
Afimetoran (BLN-256) oral capsule, once daily
PlaceboDrug
Placebo (capsule matched to afimetoran), once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in CLASI-A total scoreTime frame: Baseline to Week 24
- Proportion of participants achieving a CLASI-70 response (≥70% decrease from baseline in CLASI-A total score)Time frame: Week 24
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University Clinical Trials
San Diego, California · Recruiting
Omega Research DeBary, LLC
DeBary, Florida · Recruiting
Boeson Research MSO
Missoula, Montana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.